Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038103 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00038103 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 111 participants.
The verdict
NCT00038103, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.
Interventions
- DRUG Exemestane
- DRUG Celecoxib + Exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2002-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038103
The ClinicalTrials.gov registry entry for NCT00038103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exemestane is the first listed.
NCT00038103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038103 about?
NCT00038103 is a clinical study titled "Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen". This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.
What is the current status of trial NCT00038103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2002-01. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00038103?
The interventions under investigation include: Exemestane (DRUG), Celecoxib + Exemestane (DRUG).
Who is sponsoring clinical trial NCT00038103?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.